|
|
Strategic Perspectives: Oncology licensing strategies - how will targeted therapies affect the licensing market?Published by: Datamonitor Published: May. 15, 2002 - 139 Pages Table of ContentsEXECUTIVE SUMMARY Scope Datamonitor insight into licensing in oncology INTRODUCTION Drivers and barriers to pharmaceutical in-licensing Drivers of licensing agreements Barriers to forming licensing agreements Filling pipeline gaps with suitable products Portfolio fit Other product features Finding the right partner Sales and marketing strength Disease area expertise Experience in launching products Technical expertise Geographic presence Global reputation Sales of currently launched products Further funding options and future relationships Cultural fit IN-LICENSING BY COMPANIES WITH ONCOLOGY EXPERTISE Introduction Case study: BMS and ImClone Bristol-Myers Squibb and the cytotoxics market Erbitux to the rescue ImClone: partnering for success? So what went wrong? Peace, time and good data: the only route to a resolution Making the most of a bad situation: the long-term forecast Will a delayed launch allow competitors to steal Erbitux’s thunder? Conclusions IN-LICENSING AN ONCOLOGY PORTFOLIO Introduction Case Study: Roche and Genentech The deal that gained Roche an empire What did Roche get when it bought Genentech? US focus for Genentech Roche’s cancer portfolio in 2001 Conclusions LICENSING TO GAIN ACCESS TO NEW GEOGRAPHICAL MARKETS Introduction Case study: Pierre Fabre, GlaxoSmithKline and Navelbine Navelbine (vinorelbine) Licensing to GlaxoSmithKline Pierre Fabre’s future cytotoxic compounds GSK’s growth strategy: an attractive licensing partner? Conclusions LICENSING TO GAIN ACCESS TO THE JAPANESE MARKET Introduction Maximizing market share: effective promotion of cancer agents for out-licensers Building the ideal cancer portfolio… Case Study: Aventis, Chugai and Taxotere Aventis and Taxotere The Japanese cytotoxics market Chugai and Taxotere Conclusions Domestic firms can be useful when gaining marketing approval Japanese market now more penetrable Retaining flexibility LICENSING IN THE BIOTECH INDUSTRY Introduction Licensing deals within the biotechnology industry Case Study: Amgen, Johnson & Johnson and epoetin alfa. Amgen Epoetin alfa The out-licensing of epoetin alpha to J&J Legal issues between J&J and Amgen Amgen and J&J go head-to-head in arthritis indication Has J&J helped Amgen achive its potential? Has J&J damaged its reputation as a licensing partner? Conclusion The good, the bad and the ugly APPENDIX Datamonitor's Oncology Business Unit Primary Research methodology Primary research Opinion Leader Interviews Pipeline productivity index methodology Sales Data Research Methodology Introduction Hypothesis formulation Hypothesis testing Data verification with key contacts Quality control R&D Research Methodology Introduction Hypothesis formulation Hypothesis testing Data verification and quality control Supplementary data Brain Cancer Breast Cancer Colorectal Cancer Head & Neck Cancer Leukemia Lung Cancer Melanoma Ovarian Cancer Pancreatic Cancer Prostate Cancer Bibliography Future readings Relevant links How to contact experts in your industry © Datamonitor 2002. All Rights Reserved. AbstractStrategic Perspectives: Oncology Licensing Strategies reviews and analyses the licensing issues most relevant to the current oncology market. In today’s dynamic oncology arena, the number of classical cytotoxics — the traditional foundation of cancer pharmaceuticals organizations — in development is decreasing, while the number of immunotherapies, vaccines and small molecule drugs is increasing at an exponential rate. Few pharmaceutical companies can afford to invest heavily in the development of multiple technology platforms or in more than a few of the widely diverse products in pipeline or on the market. How can acceleration in new areas be achieved? While some pharmaceutical companies have chosen the direct route of developing technology platforms and/or purchasing companies with expertise in their areas of interest, there is an increasing, across-the-board trend toward in-licensing to provide the strength and depth of product portfolio that will help maintain a share of a rapidly expanding oncology therapeutics market. This report covers the general features of licensing decisions and the means by which effective and lucrative licensing deals can be made for both in-licenser and out-licenser. The report is based upon the most likely scenarios faced by those companies involved in-licensing issues, defined by company type. The first section covers the general issues that surround licensing, and further chapters cover licensing by pharmaceutical companies of different sizes and levels of expertise in oncology, using case studies as an informational tool. The final chapter brings together the lessons that can be learned from the case studies within each chapter and formulates a number action points that oncology R & D managers and marketing can use to develop effective licensing agreements within oncology.Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||